Marshall T. Schreeder

Author

Also Known As

M Schreeder, M T Schreeder, M. Schreeder, M. T. Schreeder, M.T. Schreeder, MARSHALL T. SCHREEDER, Marshall Schreeder, Marshall T Schreeder, Marshall T. Schreeder

131

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Clearview Cancer Institute Sarah Cannon The University of Texas MD Anderson Cancer Center Cornell University University of California, Los Angeles

About

Marshall T. Schreeder is an author at Clearview Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	33	1.3K
2	Health Sciences	11	13	372
3	Social Sciences	4	4	265
4	Business	1	1	11
5	Public Health	1	1	20

Marshall T. Schreeder

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Hepatitis B in Homosexual Men: Prevalence of Infection and Factors Related to Transmission Marshall T. Schreeder, Suzanne Thompson, Stephen C. Hadler, The Journal of Infectious Diseases Hepatitis BHomosexualityPathologyUnited StatesSocial Sciences	1982	189
Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous <scp>FOLFOX</scp> and bevacizumab for patients with unresectable colorectal liver‐limited metastasis Robert C.G. Martin, Charles R. Scoggins, Marshall T. Schreeder, Cancer	2015	149
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. John D. Hainsworth, Joan B. Erland, Leonard Kalman, Journal of Clinical Oncology	1997	134
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma Brian Z. Ring, Robert S. Seitz, Rodney A. Beck, Modern Pathology Cancer DetectionLung CarcinomaMedicineMultiple Pulmonary NoduleImmunology	2009	91
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, Blood	2019	87
Carcinoma of unknown primary site Frank A. Greco, Howard A. Burris, Joan B. Erland, Cancer	2000	84
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Annals of Oncology Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study	2023	78
Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial Robert C.G. Martin, Charles R. Scoggins, Dana Tomalty, Journal of Gastrointestinal Surgery Irinotecan Drug-eluting BeadsConcomitant Systemic FluorouracilMedicinePharmacologyColorectal Cancer	2012	76
A phase 1/2 trial of ublituximab, a novel anti‐ <scp>CD</scp> 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, British Journal of Haematology	2017	72
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, Clinical Cancer Research	2019	72

Page 1